GlassScriptPhysician profile
Amanda Grace Estep
NPI 1275978207
$9,301.13
in general payments reported to CMS, 2019-2025
51 companies · $1,478 in 2025
The $1,478 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $831 · 2021: $1,282 · 2022: $1,488 · 2023: $2,016 · 2024: $1,511 · 2025: $1,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,004.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,490.44 | 2021-2025 | |
| Novo Nordisk INC | $1,097.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,001.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $740.83 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $678.89 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $542.15 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $289.17 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.33 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $241.00 | 2019-2025 | Evenity, Prolia, Repatha |
| Allergan, INC. | $211.13 | 2019-2020 | |
| Grifols USA, LLC | $206.28 | 2022-2025 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $190.83 | 2019-2022 | |
| Astellas Pharma US INC | $182.85 | 2019-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $179.59 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $143.06 | 2021-2025 | Gattex, Trintellix, Entyvio |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Estep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.